HOUSTON, March 5, 2020 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"),
a biopharmaceutical company specializing in the development of
novel treatments for primary and metastatic cancers of the brain
and central nervous system, plans to report financial results for
the three and 12 months ended December 31,
2019, after the close of the U.S. financial markets on
Thursday, March 12, 2020.
CNS' senior management will provide a business update in a
conference call and live audio webcast at 4:30 p.m. Eastern time on Thursday, March 12,
2020. The conference call dial-in and webcast information is as
follows:
DOMESTIC
DIAL-IN:
|
(844)
535-4071
|
INTERNATIONAL
DIAL-IN:
|
(706)
679-2458
|
PASSCODE:
|
1254059
|
WEBCAST:
|
CNS Business Update
Conference Call
|
For those unable to participate in the live conference call or
webcast, a replay will be available beginning approximately two
hours after the close of the conference call. To access the replay,
dial 855-859-2056 or 404-537-3406. The replay passcode is 1254059.
The replay can be accessed for a period of time on CNS website at
CNS Business Update Conference Call.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is developing novel treatments for primary and
metastatic cancers of the brain and central nervous system. Its
lead drug candidate, Berubicin, is proposed for the treatment of
glioblastoma multiforme (GBM), an aggressive and incurable form of
brain cancer. CNS holds a worldwide exclusive license to the
Berubicin chemical compound and has acquired all data and know-how
from Reata Pharmaceuticals, Inc. related to a completed Phase 1
trial with Berubicin in GBM which Reata conducted in 2006. In
this trial, 44% of patients experienced a statistically significant
improvement in progression-free survival. This 44% disease control
rate was based on 11 patients (out of 25 evaluable patients) with
stable disease, plus responders. One patient experienced a durable
complete response and remains cancer-free as of February 20, 2020. In the second half of 2020,
CNS expects to commence a Phase 2 clinical trial of Berubicin for
the treatment of GBM in the U.S., while a sub-licensee partner
undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial
in pediatric GBM patients in Poland. Its second drug
candidate, WP1244, is a novel DNA binding agent that has shown in
preclinical studies that it is 500-times more potent than the
chemotherapeutic agent daunorubicin in inhibiting tumor cell
proliferation.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-report-fourth-quarter-2019-financial-results-on-march-12-2020-301018601.html
SOURCE CNS Pharmaceuticals, Inc.